Cullinan Therapeutics Inc [CGEM] stock is trading at $11.92, down -3.72%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CGEM shares have gain 12.56% over the last week, with a monthly amount glided 42.75%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On October 24, 2024, UBS initiated with a Buy rating and assigned a price target of $30 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $40 on May 01, 2024. William Blair initiated its recommendation with an Outperform. Wedbush started tracking with an Outperform rating for this stock on February 15, 2024, and assigned it a price target of $30. In a note dated June 15, 2023, TD Cowen initiated an Outperform rating.
Cullinan Therapeutics Inc [CGEM] stock has fluctuated between $5.68 and $13.33 over the past year. Currently, Wall Street analysts expect the stock to reach $32.67 within the next 12 months. Cullinan Therapeutics Inc [NASDAQ: CGEM] shares were valued at $11.92 at the most recent close of the market. An investor can expect a potential return of 174.08% based on the average CGEM price forecast.
Analyzing the CGEM fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.45, Equity is -0.42 and Total Capital is -0.53. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.57 points at the first support level, and at 11.21 for the second support level. However, for the 1st resistance point, the stock is sitting at 12.61, and for the 2nd resistance point, it is at 13.29.
Ratios To Look Out For
For context, Cullinan Therapeutics Inc’s Current Ratio is 10.45. Further, the Quick Ratio stands at 10.45, while the Cash Ratio is 3.15.
Transactions by insiders
Recent insider trading involved Michaelson Jennifer, Chief Scientific Officer, that happened on Nov 24 ’25 when 4000.0 shares were sold. Officer, JENNIFER MICHAELSON completed a deal on Nov 24 ’25 to buy 4000.0 shares. Meanwhile, 10% Owner Lynx1 Capital Management LP bought 0.17 million shares on Oct 28 ’25.
